Patents Examined by San Ming R. Hui
  • Antifungal agents
    Patent number: 11065228
    Abstract: The invention provides a pyrrole compound, which compound is (a) 2-(1,5-dimethyl-3-phenyl-1H-pyrrol-2-yl)-N-(4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)phenyl)-2-oxoacetamide or a deuterated derivative thereof, or (b) 2-(1,5-dimethyl-3-phenyl-1H-pyrrol-2-yl)-N-(4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)-3-hydroxyphenyl)-2-oxoacetamide or a deuterated derivative thereof, or (c) a prodrug of compound (a) or a prodrug of compound (b), or a pharmaceutically acceptable salt or agriculturally acceptable salt of (a), (b) or (c). Also provided are combinations and compositions comprising the compound and known antifungal agents. The invention also relates to the therapeutic use of a compound of the invention in prevention or treatment of fungal diseases.
    Type: Grant
    Filed: February 10, 2020
    Date of Patent: July 20, 2021
    Assignee: F2G Limited
    Inventors: Graham Edward Morris Sibley, Derek Law, Jason David Oliver, Michael Birch
  • Bupropion as a modulator of drug activity
    Patent number: 11058648
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: November 16, 2020
    Date of Patent: July 13, 2021
    Assignee: Antecip Bioventures II LLC
    Inventor: Herriot Tabuteau
  • Uses of benzimidazole derivative for nocturnal acid breakthrough
    Patent number: 11033532
    Abstract: The present invention relates to a use of benzimidazole derivative compounds for improvement and treatment of nocturnal acid breakthrough (NAB). The benzimidazole derivative compounds can more effectively prevent and treat gastric acid-related diseases by effectively improving and treating nocturnal nocturnal acid breakthrough symptoms.
    Type: Grant
    Filed: November 7, 2019
    Date of Patent: June 15, 2021
    Assignee: HK INNO.N CORPORATION
    Inventors: Ha Jin Lee, Bong Tae Kim, Hyun Kim, Ji Yeon Nam, Jie Eun Park, Geun Seog Song, Shin Young Ryu, Shinichi Koizumi, Nobuyuki Takahashi, Masaomi Tajimi
  • Use of carbamate compound for preventing, alleviating, or treating tremors or tremor syndrome
    Patent number: 11033531
    Abstract: The present invention relates to a use of a pharmaceutical composition which includes a carbamate compound of chemical formula 1 and is administered to prevent, alleviate, or treat tremors or tremor syndrome.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: June 15, 2021
    Assignee: SK BIOPHARMACEUTICALS CO., LTD.
    Inventors: Jin Uk Yoo, Hye Sung Lee, Han Ju Yi
  • Non-hormonal treatment of the genitourinary syndrome of menopause
    Patent number: 11033527
    Abstract: Methods of treating the genitourinary syndrome of menopause (GSM) and modulating expression of genes involved in the GSM in an individual include administering compound L759,633 or compound JWH-133, both selective ligands for the endocannabinoid receptor type 2 (CB2). These compounds and compositions containing these compounds can be used as a non-hormonal alternative to hormones such as estrogen and ospemiphene for the treatment of the GSM and in particular, vaginal atrophy (VVA).
    Type: Grant
    Filed: February 7, 2019
    Date of Patent: June 15, 2021
    Assignee: IMMUGEN PHARMA LLC
    Inventor: Craig R. Travis
  • Dosage regimen, medication dispensing package and uses thereof for the treatment of major depressive disorder
    Patent number: 11013721
    Abstract: This invention provides an oral dosage regimen for the treatment of depression, a pharmaceutically acceptable medication dispensing package containing multiple dosage units of medicaments comprising an oral dosage regimen of D-cycloserine for the treatment of depression, a pharmaceutical composition comprising D-cycloserine formulated for oral administration providing a dosage of 1000 mg/day alone or in combination with antidepressant agents and uses thereof.
    Type: Grant
    Filed: October 10, 2019
    Date of Patent: May 25, 2021
    Assignee: SARAH HERZOG MEMORIAL HOSPITAL EZRAT NASHIM ASSOCIATION
    Inventors: Uriel Heresco-Levy, Daniel Javitt
  • Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3
    Patent number: 11007204
    Abstract: Methods and compositions for treating 25-hydroxyvitamin D insufficiency and deficiency in a patient are described herein. The method includes orally administering to the patient a delayed, sustained release formulation including a first ingredient selected from the group consisting of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3, or it includes gradually administering to the patient a sterile intravenous formulation including a first ingredient selected from the group consisting of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: May 18, 2021
    Assignee: OPKO RENAL, LLC
    Inventors: Charles W. Bishop, Keith H. Crawford, Eric J. Messner
  • Antifungal compounds
    Patent number: 11000514
    Abstract: The technical field of the invention is in pharmaceutical compounds and methods. In an aspect, the disclosure provides macrolide compounds suitable for use as antifungal agents, as well as methods for their use and compositions containing the same.
    Type: Grant
    Filed: February 20, 2020
    Date of Patent: May 11, 2021
    Assignee: Duke University
    Inventors: Jonathan A. Covel, Mitchell Mutz, Peter J. Webb, Robert Remme Webb, II
  • Compositions for improving sexual function
    Patent number: 10993924
    Abstract: The present invention relates to compositions comprising L-arginine and L-citrulline in specific ratios. In particular, the present invention relates to the use of such compositions for improving sexual function in a healthy human subject.
    Type: Grant
    Filed: December 6, 2019
    Date of Patent: May 4, 2021
    Assignee: INXO A/S
    Inventors: Djamaluddin Zaferan, Jahangir Khan
  • Exogenous ketone supplements for reducing anxiety-related behavior
    Patent number: 10980764
    Abstract: Methods of treating anxiety disorders or reducing anxiety-related behaviors. The methods include administering a therapeutically effective amount of ketone supplementation, such as butanediol, ketone esters (e.g., 1,3-butanediol-acetoacetate diester) and/or ketone salts (e.g., beta-hydroxybutyrate-mineral salt), chronically, sub-chronically, or acutely, with or without admixture with a medium chain triglyceride or in combination. It was determined herein that ketone supplementation reduced anxiety in rats on elevated plus maze as measured by less entries to closed arms, more time spent in open arms, more distance travelled in open arms, and delayed latency to entrance to closed arms, when compared to control. Along with reducing anxiety-related behavior, the chronic, sub-chronic, and acute ketone supplements also caused significant elevation of blood ?HB levels and changed blood glucose levels.
    Type: Grant
    Filed: February 1, 2017
    Date of Patent: April 20, 2021
    Assignee: University of South Florida
    Inventors: Csilla Ari D'Agostino, Dominic Paul D'Agostino
  • Epinephrine spray formulations
    Patent number: 10973781
    Abstract: The present invention is directed to epinephrine spray formulations. The present invention is further directed to methods of treating anaphylaxis by administering epinephrine spray formulations to subjects in need of such treatments.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: April 13, 2021
    Assignee: HIKMA PHARMACEUTICALS USA INC.
    Inventors: Thrimoorthy Potta, Craig Bastian, Ningxin Yan, Venkat Goskonda, Chandeshwari Chilampalli, Rachana Inavolu, Eshwaran Narayanan
  • Dental composition and use
    Patent number: 10973794
    Abstract: Use of a composition for the prevention, amelioration and/or treatment of conditions, disorders and/or diseases associated with senescence and/or inflammation of the teeth and/or associated structures and tissues in the mouth, the composition comprising a conjugate of quinic acid with at least one molecule of caffeic acid, or a derivative, isomer or salt thereof.
    Type: Grant
    Filed: February 10, 2016
    Date of Patent: April 13, 2021
    Assignee: CALSCIENCE INTERNATIONAL LTD.
    Inventors: Iain William George Forbes, William Forbes
  • Epinephrine spray formulations
    Patent number: 10966925
    Abstract: The present invention is directed to epinephrine spray formulations. The present invention is further directed to methods of treating anaphylaxis by administering epinephrine spray formulations to subjects in need of such treatments.
    Type: Grant
    Filed: January 4, 2019
    Date of Patent: April 6, 2021
    Assignee: HIKMA PHARMACEUTICALS USA INC.
    Inventors: Thrimoorthy Potta, Craig Bastian, Ningxin Yan, Venkat Goskonda, Chandeshwari Chilampalli, Rachana Inavolu, Eshwaran Narayanan
  • Modified release doxycycline composition
    Patent number: 10953022
    Abstract: Doxycycline formulations with a reduced food effect are disclosed. Particularly disclosed are modified release formulations which can be administered once a day and exhibit a reduced food effect. Methods of treating inflammatory conductions such as rosacea or inflammatory symptoms such as the papules and pustules of rosacea or acne vulgaris are also disclosed.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: March 23, 2021
    Assignee: GALDERMA HOLDING SA
    Inventors: Ankit Baheti, Bijay Kumar Padhi, Rajeev Singh Raghuvanshi
  • Delaying latency to seizure by combinations of ketone supplements
    Patent number: 10945975
    Abstract: Provided herein are compositions and methods for preventing central nervous system oxygen toxicity in a subject.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: March 16, 2021
    Assignee: University of South Florida
    Inventors: Csilla Ari D'Agostino, Dominic Paul D'Agostino, Jay B. Dean
  • Methods for the administration of certain VMAT2 inhibitors
    Patent number: 10940141
    Abstract: Provided is a method of administering a vesicular monoamine transporter 2 (VMAT2) inhibitor to a subject in need thereof, wherein the subject has severe renal impairment.
    Type: Grant
    Filed: August 10, 2020
    Date of Patent: March 9, 2021
    Assignee: Neurocrine Biosciences, Inc.
    Inventors: Gordon Raphael Loewen, Sha Rosa Luo
  • Neuroactive steroids, compositions, and uses thereof
    Patent number: 10940156
    Abstract: Described herein are methods of treating a disorder, e.g., tremor, e.g., essential tremor; depression, e.g., postpostum depression; and anxiety disorder, the method comprising administering to a human subject suffering from a disorder, e.g., tremor, e.g., essential tremor; depression, e.g., postpostum depression, an anxiety disorder with a neuroactive steroid or a composition comprising a neuroactive steroid (e.g., pregnanolone, allopregnanolone, alphadalone, ganaxolone, or alphaxolone).
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: March 9, 2021
    Assignee: Sage Therapeutics, Inc.
    Inventors: Stephen Jay Kanes, Helen Colquhoun
  • Dipyridamole for use in treating SLC29A2 nuclear-expressing cancer
    Patent number: 10912777
    Abstract: A pharmaceutical composition comprising (i) a therapeutically effective amount of an inhibitor of the oncogene SLC29A2; and (ii) a pharmaceutically acceptable carrier, for use in suppressing proliferation, occurrence, and metastasis of cancer cells overexpressing the oncogene SLC29A2 in a cancer patient, and/or prolonging cancer patient survival. The inhibitor of the oncogene SLC29A2 may be at least one selected from the group consisting of dipyridamole, dilazep, draflzine, nitorbenzylthioinosine, and the derivatives thereof. The composition for use may further comprise sorafenib for the same use.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: February 9, 2021
    Assignee: ACADEMIA SINICA
    Inventors: Yuh-Shan Jou, Roger Shen
  • Point mutations in TRK inhibitor-resistant cancer and methods relating to the same
    Patent number: 10907215
    Abstract: Provided herein are methods of treating a subject having a cancer, methods of selecting a treatment for a subject having a cancer, methods of selecting a subject having a cancer for a treatment that does not include a Trk inhibitor, methods of determining the likelihood that a subject having a cancer will have a positive response to a treatment with a Trk inhibitor, methods of predicting the efficacy of a Trk inhibitor in a subject having cancer, methods of determining a subject's risk for developing a Trk inhibitor-resistant cancer, and methods of determining the presence of a Trk inhibitor-resistant cancer in a subject, based on the detection of a cell from a sample from the subject that has at least one of the the point mutations in NTRK1 and/or NTRK2 and/or NTRK3.
    Type: Grant
    Filed: January 3, 2018
    Date of Patent: February 2, 2021
    Assignees: Loxo Oncology, Inc., Array BioPharma, Inc.
    Inventors: Nisha Nanda, Joshua H. Bilenker, James F. Blake, Gabrielle R. Kolakowski, Barbara J. Brandhuber, Steven W. Andrews
  • Inhibition of galectin 3 binding to the airway epithelial surface to treat or prevent septic shock resulting from influenza and subsequent pneumococcal pneumonia infection
    Patent number: 10905702
    Abstract: Galectin 3 inhibitors and methods for treating sepsis using the same are provided herein.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: February 2, 2021
    Assignees: UNIVERSITY OF MARYLAND, BALTIMORE, UNIVERSITY OF MARYLAND
    Inventors: Gerardo Vasta, Lai-Xi Wang